Citations

Clear

4802 citation(s) found for "Yu, Jennifer".

Autopsy Validation of Progressive Supranuclear Palsy‐Predominant Speech/Language Disorder Criteria
Hokelekli, Fatma Ozlem , Utianski, Rene L. , Ali, Farwa , Stierwalt, Julie A. G., Reichard, R. Ross , Whitwell, Jennifer L. , Josephs, Keith A. , Utianski, Rene L , Stierwalt, Julie A, Whitwell, Jennifer , Josephs, Keith A , Duffy, Joseph R. , Clark, Heather M. , Botha, Hugo , Machulda, Mary M. , Dickson, Dennis W.

Mayo Clinic

Movement Disorders | October 11, 2021 | Volume: 37 | Issue: 1 | Pages: 213-218

10.1002/mds.28822 | PMID 34632629 Get It

ABSTRACTBackgroundProgressive supranuclear palsy (PSP) may present as a speech/language disorder (PSP‐SL).ObjectiveWe assessed pathological correlates of patients with PSP‐SL who retained the suggestive of PSP‐SL (s.o. PSP‐SL) diagnosis versus those who progressed to possible/probable (poss./prob.) PSP.MethodsThirty‐four prospectively recruited patient with s.o. PSP‐SL completed comprehensive speech/language and neurological assessments longitudinally, died, and underwent autopsy.ResultsTwelve patients (35%) evolved to poss./prob PSP, while 22 (65%) remained as s.o. PSP‐SL. Pathological diagnoses differed across the groups (P = 0.025). Patients with s.o. PSP‐SL had four different neuropathologies (corticobasal degeneration [59%], PSP [13%], Pick's disease [14%], and frontotemporal lobar degeneration with TDP‐43 [14%]), while all patients with poss./prob. PSP had a 4R‐tauopathy (PSP [67%] and corticobasal degeneration [33%]). Development of poss./prob. PSP increased the chance of having PSP pathology by 2.38 times.ConclusionsPSP‐SL is associated with heterogenous pathologies. Evolution of PSP‐SL into poss./prob. PSP is more predictive of underlying PSP pathology than s.o. PSP‐SL. © 2021 International Parkinson and Movement Disorder Society
Immune‐mediated necrotizing myopathy: Unusual presentations of a treatable disease
Nicolau, Stefan , Milone, Margherita , Tracy, Jennifer A., Mills, John R. , Triplett, James , Liewluck, Teerin , Triplett, James D, Liewluck, T , Nicolau, Stefan , Triplett, James D

Mayo Clinic

Muscle & Nerve | October 8, 2021 | Volume: 64 | Issue: 6 | Pages: 734-739

10.1002/mus.27435 | PMID 34617293 Get It

AbstractIntroduction/AimsImmune‐mediated necrotizing myopathy (IMNM) is an immune‐mediated myopathy typically presenting with progressive subacute weakness and characteristic, but nonspecific, myopathological findings. Atypical cases however can mimic other inherited or acquired myopathies, depriving patients of treatment. We describe a cohort of such patients.MethodsWe retrospectively identified IMNM patients who either previously carried a diagnosis of an inherited myopathy established on clinicopathological grounds or whose muscle biopsies displayed atypical features suggestive of a different myopathy.ResultsAmong 131 IMNM patients, seven previously unreported patients (5%) met one of the above criteria. Three patients were diagnosed with limb‐girdle muscular dystrophy on the basis of a chronic progressive course of weakness and family history of myopathy or cardiomyopathy. The other four patients displayed atypical histological features (two prominent mitochondrial abnormalities, one myofibrillar pathology, and one granulomatous inflammation). Immunostaining of biopsies from 12 additional IMNM patients did not identify myofibrillar pathology. The patient with granulomatous inflammation was known to have pulmonary sarcoidosis. Genetic testing for inherited myopathies was unrevealing. Antibodies against 3‐hydroxy‐3‐methylglutaryl‐CoA reductase or signal recognition particle were identified in 5 and 1 patients, respectively. Four patients presented with slowly progressive weakness over 3–13 y, while weakness was subacute over ≤6 mo in three patients. All patients responded to immunomodulatory therapy.DiscussionAtypical clinical and histological features can occur in IMNM patients, causing delays in diagnosis and treatment. Clinicians should, therefore, consider IMNM in the differential diagnosis of unexplained proximal myopathies in spite of atypical clinical and myopathological findings.
Modulation of fracture healing by the transient accumulation of senescent cells
Saul, Dominik , Rowsey, Jennifer L. , Kosinsky, Robyn Laura , Vos, Stephanie J. B. , Farr, Joshua N. , Khosla, Sundeep , Vos, Stephanie J, Doolittle, Madison L. , Farr, Joshua N , Khosla, Sundeep , Kosinsky, Robyn Laura , Saul, Dominik , Monroe, David G. , Vos, Stephanie J

Mayo Clinic

eLife | October 7, 2021 | Volume: 10 | Issue: No issue available | Pages: No page available

10.7554/elife.69958 | PMID 34617510 Get It

Senescent cells have detrimental effects across tissues with aging but may have beneficial effects on tissue repair, specifically on skin wound healing. However, the potential role of senescent cells in fracture healing has not been defined. Here, we performed an in silico analysis of public mRNAseq data and found that senescence and senescence-associated secretory phenotype (SASP) markers increased during fracture healing. We next directly established that the expression of senescence biomarkers increased markedly during murine fracture healing. We also identified cells in the fracture callus that displayed hallmarks of senescence, including distension of satellite heterochromatin and telomeric DNA damage; the specific identity of these cells, however, requires further characterization. Then, using a genetic mouse model ( Cdkn2a LUC ) containing a Cdkn2a Ink4a -driven luciferase reporter, we demonstrated transient in vivo senescent cell accumulation during callus formation. Finally, we intermittently treated young adult mice following fracture with drugs that selectively eliminate senescent cells (‘senolytics’, Dasatinib plus Quercetin), and showed that this regimen both decreased senescence and SASP markers in the fracture callus and significantly accelerated the time course of fracture healing. Our findings thus demonstrate that senescent cells accumulate transiently in the murine fracture callus and, in contrast to the skin, their clearance does not impair but rather improves fracture healing.
V.I.T.A.M. in COVID 19: A Systematic Approach to a Global Pandemic
Yarrarapu, Siva Naga S. , Bansal, Pankaj , Cusick, Austin , Melody, Megan , Moktan, Varun , Rivero, Andrea , Brigham, Tara , Brumble, Lisa , OʼBrien, Jennifer , Lee, Augustine S. , Klaus, Torp, Santos, Christan D. , Rivera, Candido E., Siegel, Jason , Sanghavi, Devang , Brigham, Tara J, Jennifer, J O'brein, Lee, Augustine, Santos, Christan, Rivera, Candido, Brigham, T J , Bansal, Pankaj , Yarrarapu, Siva Naga S , Abia‐Trujillo, David , Rivero, Andrea, Libertin, Claudia R. , Guru, Pramod , Franco, Pablo Moreno

Mayo Clinic

Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine | October 5, 2021 | Volume: 15 | Issue: No issue available | Pages: No page available

10.1177/11795484211047432 | PMID 34629922 Get It

Introduction In the unprecedented era of COVID-19, ongoing research and evolution of evidence has led to ever-changing guidelines for clinical monitoring and therapeutic options. Formulating treatment protocols requires the understanding and application of the evolving research. Objective The primary objective of this study is to present a systematic evidence-based approach to synthesize the necessary data in order to optimize the management of COVID-19. Methods At Mayo Clinic Florida, we developed a multidisciplinary centralized COVID Treatment Review Panel (TRP) of expert pulmonologists, intensivists, infectious disease specialists, anesthesiologists, hematologists, rheumatologists, and hospitalists that in real-time reviews the latest evidence in peer-reviewed journals, the available clinical trials, and help guide the rapid application of therapeutics or interventions to the patient and the bedside provider. Results/Conclusions The multi-disciplinary team approach of synthesizing clinical data and coordinating care is effective in responding to rapidly evolving and changing evidence. Systematic data collection and evidence-based treatment algorithms enable physicians to rapidly translate the current literature to clinical practice, and improve care and outcomes of patients.
Cardiac Surgery in Women in the Current Era: What Are the Gaps in Care?
Cho, Leslie , Kibbe, Melina R. , Bakaeen, Faisal G. , Aggarwal, Niti R., Davis, Melinda B. , Karmalou, Tara, Lawton, Jennifer S. , Ouzounian, Maral , Preventza, Ourania , Russo, Andrea M. , Zwischenberger, Brittany A. , Shroyer, Annie-Laurie W , Shroyer, A. Laurie , Lindley, Kathryn J

Mayo Clinic

Circulation | October 4, 2021 | Volume: 144 | Issue: 14 | Pages: 1172-1185

10.1161/circulationaha.121.056025 | PMID 34606298 Get It

Cardiovascular disease remains the leading cause of morbidity and mortality for women in United States and worldwide. One in 3 women dies from cardiovascular disease, and 45% of women >20 years old have some form of CVD. Historically, women have had higher morbidity and mortality after cardiac surgery. Sex influences pathogenesis, pathophysiology, presentation, postoperative complications, surgical outcomes, and survival. This review summarizes current cardiovascular surgery outcomes as they pertain to women. Specifically, this article seeks to address whether sex disparities in research, surgical referral, and outcomes still exist and to provide strategies to close these gaps. In addition, with the growing population of women of reproductive age with cardiovascular disease and cardiovascular risk factors, indications for cardiac surgery arise in pregnant women. The current review will also address the unique issues associated with this special population.
Consensus practice guidelines on interventions for cervical spine (facet) joint pain from a multispecialty international working group
Hurley, Robert W. , Adams, Meredith C B , Barad, Meredith , Bhaskar, Arun , Bhatia, Anuj , Deer, Timothy R. , Hah, Jennifer M. , Hooten, W. Michael , Lee, David Wonhee, McCormick, Zachary L. , Schneider, Byron J. , Eerd, Maarten van , Zundert, Jan Van , Wallace, Mark S. , Wilson, Sara M, Zhao, Zirong , Chadwick, Andrea , Deer, Tim , Hooten, W Michael , Moon, Jee Youn , Narouze, Samer , Cohen, Steven P , van Zundert, Jan , Hurley, Robert W , Barad, Meredith J , Hah, Jennifer M , Bhatia, Anuj , Kissoon, Narayan , Narouze, Samer , Provenzano, David , Cohen, Steven P.

Mayo Clinic

Pain Medicine | October 1, 2021 | Volume: 22 | Issue: 11 | Pages: 2443-2524

10.1093/pm/pnab281 | PMID 34788462 Get It

Abstract Background The past two decades have witnessed a surge in the use of cervical spine joint procedures including joint injections, nerve blocks and radiofrequency ablation to treat chronic neck pain, yet many aspects of the procedures remain controversial. Methods In August 2020, the American Society of Regional Anesthesia and Pain Medicine and the American Academy of Pain Medicine approved and charged the Cervical Joint Working Group to develop neck pain guidelines. Eighteen stakeholder societies were identified, and formal request-for-participation and member nomination letters were sent to those organizations. Participating entities selected panel members and an ad hoc steering committee selected preliminary questions, which were then revised by the full committee. Each question was assigned to a module composed of 4–5 members, who worked with the Subcommittee Lead and the Committee Chairs on preliminary versions, which were sent to the full committee after revisions. We used a modified Delphi method whereby the questions were sent to the committee en bloc and comments were returned in a non-blinded fashion to the Chairs, who incorporated the comments and sent out revised versions until consensus was reached. Before commencing, it was agreed that a recommendation would be noted with >50% agreement among committee members, but a consensus recommendation would require ≥75% agreement. Results Twenty questions were selected, with 100% consensus achieved in committee on 17 topics. Among participating organizations, 14 of 15 that voted approved or supported the guidelines en bloc, with 14 questions being approved with no dissensions or abstentions. Specific questions addressed included the value of clinical presentation and imaging in selecting patients for procedures, whether conservative treatment should be used before injections, whether imaging is necessary for blocks, diagnostic and prognostic value of medial branch blocks and intra-articular joint injections, the effects of sedation and injectate volume on validity, whether facet blocks have therapeutic value, what the ideal cut-off value is for designating a block as positive, how many blocks should be performed before radiofrequency ablation, the orientation of electrodes, whether larger lesions translate into higher success rates, whether stimulation should be used before radiofrequency ablation, how best to mitigate complication risks, if different standards should be applied to clinical practice and trials, and the indications for repeating radiofrequency ablation. Conclusions Cervical medial branch radiofrequency ablation may provide benefit to well-selected individuals, with medial branch blocks being more predictive than intra-articular injections. More stringent selection criteria are likely to improve denervation outcomes, but at the expense of false-negatives (ie, lower overall success rate). Clinical trials should be tailored based on objectives, and selection criteria for some may be more stringent than what is ideal in clinical practice.
Trends in utilization of non‐first‐line topical acne medications among children, adolescents, and adults in the United States, 2012‐2016
Afarideh, Mohsen , Baisi, Katinna E. Rodriguez , Davis, Dawn Marie R. , Hand, Jennifer L. , Tollefson, Megha M. , Rodriguez Baisi, Katinna , Davis, Dawn M R

Mayo Clinic

Pediatric Dermatology | October 1, 2021 | Volume: 38 | Issue: 5 | Pages: 1066-1073

10.1111/pde.14733 | PMID 34595751 Get It

AbstractBackground/ObjectiveCurrent knowledge about usage of effective, but non‐first‐line topical acne medications in the United States is limited. We aimed to investigate utilization patterns and temporal trends for such acne medications in the US ambulatory care.MethodsPediatric (≤18 years old) and adult (>18 years old) data from the 2012 to 2016 (inclusive) cycles of the US National Ambulatory Medical Care Survey were extracted. Utilization patterns of six non‐first‐line topical acne medications (ie, azelaic acid, salicylic acid, glycolic acid, sulfur, resorcinol, and zinc) were compared and followed over time.ResultsData from 218 410 US office–based sampled visits during 2012‐2016 were included in the analysis. Across all acne visits (n = 1542), salicylic acid (1.58%), azelaic acid (1.22%), and glycolic acid (0.52%) were the most frequently used agents, while zinc and resorcinol were not used. Sulfur (0.52%) and salicylic acid (0.33%) were the only medications used in preadolescents, and none of these medications were used in the neonatal or infantile group. Temporal trends for using at least one of these medications were insignificant among both pediatric and adult age groups (P = .825 and .136, respectively).ConclusionsSalicylic acid and azelaic acid are the most frequently used of the studied second‐line medications to treat acne, although the use of these and the other non‐first‐line topical medications overall is uncommon, especially among younger groups of US pediatric patients.
Provider Perspectives on the Acceptability, Appropriateness, and Feasibility of Teleneonatology
Fang, Jennifer L. , Umoren, Rachel , Whyte, Hilary, Limjoco, Jamie , Yankanah, Rosanna, McCoy, Mike, Lo, Mark D., Colby, Christopher E. , Jacobson, Robert M. , Makkar, Abhishek , Herrin, Jeph , Demaerschalk, Bart M.

Mayo Clinic

American Journal of Perinatology | September 28, 2021 | Volume: 40 | Issue: 14 | Pages: 1521-1528

10.1055/a-1656-6363 | PMID 34583392 Get It

Objective We aimed to measure provider perspectives on the acceptability, appropriateness, and feasibility of teleneonatology in neonatal intensive care units (NICUs) and community hospitals. Study Design Providers from five academic tertiary NICUs and 27 community hospitals were surveyed using validated implementation measures to assess the acceptability, appropriateness, and feasibility of teleneonatology. For each of the 12 statements, scale values ranged from 1 to 5 (1 = strongly disagree; 5 = strongly agree), with higher scores indicating greater positive perceptions. Survey results were summarized, and differences across respondents assessed using generalized linear models. Results The survey response rate was 56% (203/365). Respondents found teleneonatology to be acceptable, appropriate, and feasible. The percent of respondents who agreed with each of the twelve statements ranged from 88.6 to 99.0%, with mean scores of 4.4 to 4.7 and median scores of 4.0 to 5.0. There was no difference in the acceptability, appropriateness, and feasibility of teleneonatology when analyzed by professional role, years of experience in neonatal care, or years of teleneonatology experience. Respondents from Level I well newborn nurseries had greater positive perceptions of teleneonatology than those from Level II special care nurseries. Conclusion Providers in tertiary NICUs and community hospitals perceive teleneonatology to be highly acceptable, appropriate, and feasible for their practices. The wide acceptance by providers of all roles and levels of experience likely demonstrates a broad receptiveness to telemedicine as a tool to deliver neonatal care, particularly in rural communities where specialists are unavailable. Key Points
Clinical Considerations for Routine Auditory and Vestibular Monitoring in Patients With Cystic Fibrosis
Garinis, Angela C. , Poling, Gayla L. , Konrad‐Martin, Dawn , Hullar, Timothy E. , Burrows, Holly , Chisholm, Jennifer , Custer, Amy , Hawe, Laura Dreisbach, Hunter, Lisa L. , Marras, Theodore K. , Ortiz, Candice E., Petersen, Lucretia , Winthrop, Kevin , Zettner, Erika M., Clark, Khaya D. , Hungerford, Michelle, Vachhani, Jay J., Brewer, Carmen C. , Steyger, Peter S , Clark, Khaya , Poling, Gayla L , Rubenstein, Ronald C. , Baguley, David

Mayo Clinic

American Journal of Audiology | September 22, 2021 | Volume: 30 | Issue: 3S | Pages: 800-809

10.1044/2021_aja-21-00031 | PMID 34549989 Get It

Purpose Specific classes of antibiotics, such as aminoglycosides, have well-established adverse events producing permanent hearing loss, tinnitus, and balance and/or vestibular problems (i.e., ototoxicity). Although these antibiotics are frequently used to treat pseudomonas and other bacterial infections in patients with cystic fibrosis (CF), there are no formalized recommendations describing approaches to implementation of guideline adherent ototoxicity monitoring as part of CF clinical care. Method This consensus statement was developed by the International Ototoxicity Management Working Group (IOMG) Ad Hoc Committee on Aminoglycoside Antibiotics to address the clinical need for ototoxicity management in CF patients treated with known ototoxic medications. These clinical protocol considerations were created using consensus opinion from a community of international experts and available evidence specific to patients with CF, as well as published national and international guidelines on ototoxicity monitoring. Results The IOMG advocates four clinical recommendations for implementing routine and guideline adherent ototoxicity management in patients with CF. These are (a) including questions about hearing, tinnitus, and balance/vestibular problems as part of the routine CF case history for all patients; (b) utilizing timely point-of-care measures; (c) establishing a baseline and conducting posttreatment evaluations for each course of intravenous ototoxic drug treatment; and (d) repeating annual hearing and vestibular evaluations for all patients with a history of ototoxic antibiotic exposure. Conclusion Increased efforts for implementation of an ototoxicity management program in the CF care team model will improve identification of ototoxicity signs and symptoms, allow for timely therapeutic follow-up, and provide the clinician and patient an opportunity to make an informed decision about potential treatment modifications to minimize adverse events. Supplemental Material https://doi.org/10.23641/asha.16624366
Ketamine for treatment‐resistant bipolar depression—need for more data!
Singh, Balwinder , Voort, Jennifer L. Vande , Kung, Simon , Vande Voort, Jennifer L., Singh, Balwinder

Mayo Clinic

Bipolar Disorders | September 22, 2021 | Volume: 23 | Issue: 7 | Pages: 728-729

10.1111/bdi.13129 | PMID 34549861 Get It